

MARINE CHEMILUMINESCENCE AS ANTI-TUMOR THERAPY WITH ENHANCED TUMOR-SELECTIVITY AND ACTIVITY

Carla M. Magalhães*, Patrícia González-Berdullas, Joaquim C.G. Esteves da Silva, Luís Pinto da Silva

Centro de Investigação em Química, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 687, P-4169-007 Porto, Portugal

* up201201533@fc.up.pt

Cancer is the second-highest cause of death worldwide, still being a challenging disease to treat. Thus, more efficient antitumor therapies are needed.

To this end, we have developed several single-molecule photosensitizers capable of intracellular and tumor-selective self-activation due to a chemiluminescence reaction triggered solely by a cancer marker [1,2]. Chemiluminescence consists in the conversion of thermal energy into excitation energy and subsequent light emission due to a chemical reaction [3]. This is a widespread phenomenon in nature, especially in the oceans, in which Coelenterazine is the most representative chemiluminescent substrate [3].

Herein, we developed Coelenterazine single-molecule derivatives which chemiluminescent reaction is triggered solely by a cancer marker [1,2]. Moreover, these compounds are directly chemiexcited to triplet excited states capable of generating the highly cytotoxic singlet oxygen, without requiring either a light source or any catalyst or co-factor (Figure 1).

Encouragingly, in vitro cytotoxicity assays demonstrated that these new compounds induced significant toxicity toward different tumor cell types [1,2]. In fact, this cytotoxic effect was better than the one induced by reference drugs. Furthermore, while these molecules were able to destroy tumor cells, they did not induce any toxicity toward non-cancer cells in the same concentration range [1,2].

Given this, our results indicate that the novel Coelenterazine derivatives have potential for anti-tumor therapy with enhanced tumor-selectivity and activity.




Fig.1. Proposed anti-tumor mechanism for the single-molecule Coelenterazine derivatives.

Acknowledgments

CM Magalhães acknowledges FCT for the PhD grant (SFRH/BD/143211/2019). Project PTDC/QEQ-QFI/0289/2014.

References

- [1] L. Pinto da Silva, A. Núñez-Montenegro, C.M. Magalhães, P.J.O. Ferreira, D. Duarte, P. González-Berdullas, J.E. Rodríguez-Borges, N. Vale, J.C.G. Esteves da Silva, *Eur. J. Med. Chem.*, 183 (2019) 111683.
- [2] L. Pinto da Silva, C.M. Magalhães, A. Núñez-Montenegro, PJO Ferreira, D. Duarte, J.E. Rodríguez-Borges, N. Vale, J.C.G. Esteves da Silva, *Biomolecules*, 20 (2019) E384.
- [3] C.M. Magalhães, J.C.G. Esteves da Silva, L. Pinto da Silva, *ChemPhysChem*, 17 (2016) 2286.